ClinicalTrials.gg
Drug

Mirvetuximab soravtansine clinical trials

Also written IMGN853 and Elahere.

Its developmentBy 5 companies, company by company15 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.
studies test it
28
open now
10
in phase 3
5
first study started
2012

How each study uses mirvetuximab soravtansine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the mirvetuximab soravtansine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
14 Nov 2022 · ELAHERE · BLA 761310 (FDA, Drugs@FDA)
European Union
14 Nov 2024 · Elahere · EMEA/H/C/005036 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Mirvetuximab Soravtansine
22
MIRV
10
M9346A-sulfo-SPDB-DM4
3

Brand

Elahere
2

Development codes

IMGN853
16
TAK-853
1

Studies by the year they started

28 studies that test it; most in 2021 (4)

Studies that test mirvetuximab soravtansine, by start year
YearStudies
20121
20162
20173
20181
20192
20203
20214
20222
20232
20241
20254
20263

By phase

A phase 1/2 study counts in both.

Phase 1
8
Phase 2
18
Phase 3
5

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 16 · Other 12

AbbVie (7) · ImmunoGen, Inc. (4) · Takeda (1) · Dana-Farber Cancer Institute (1) · AGO Research GmbH (1) · City of Hope Medical Center (1) · Ohio State University Comprehensive Cancer Center (1) · Pfizer (1)

Often tested with

Tested in the same studies.

Bevacizumab (2) · Carboplatin (2) · Suvemcitug (2) · Rucaparib (1) · Influenza Vaccines (1) · Paclitaxel (1) · Liposomal doxorubicin (1) · Doxorubicin (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 2 phase 3 studies under way

Mirvetuximab soravtansine is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 5, 1 in phase 3

Studies that test mirvetuximab soravtansine, phase 3 first.

Studies

Open first, then newest update. How each study uses mirvetuximab soravtansine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 28

See all 28 studies that test mirvetuximab soravtansine →

Given beside what is tested · 1 — mirvetuximab soravtansine is usual care or a partner of the new treatment
As the comparator · 2 — what is tested is compared with mirvetuximab soravtansine

What changed recently

From the registry's own updates since Oct 19, 2026.

Codes

What other systems call mirvetuximab soravtansine · ClinicalTrials.gg INT000444

  • MeSH (NLM) C000607289mirvetuximab soravtansineConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 98DE7VN88DMIRVETUXIMAB SORAVTANSINEConfirmed FDA, NLM, Wikidata
  • RxNorm 2621548One source FDA
  • Wikidata Q115285803mirvetuximab soravtansineConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C102566Mirvetuximab SoravtansineOne source FDA
  • DrugBank DB12489One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.